Analysts are intrested in these 5 stocks: ( ($IMUX) ), ( ($X) ), ( ($KLAC) ), ( ($IIPR) ) and ( ($GT) ). Here is a breakdown ...

Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases.

Fintel reports that on March 25, 2025, William Blair initiated coverage of Immunic (NasdaqGS:IMUX) with a Outperform ...

View Our Latest Report on IMUX Immunic Trading Down 5.2 % IMUX stock opened at $1.00 on Friday. The stock has a 50-day moving average price of $1.09 and a two-hundred day moving average price of ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today ...

Analysts at William Blair issued their FY2026 EPS estimates for shares of Immunic in a research note issued to investors on ...

Immunic (IMUX – Research Report) received a Buy rating and a $1.20 price target from William Blair analyst Matt Phipps yesterday. The company’s ...

NEW YORK, March 3, 2025 – Immunic , Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and ...

NEW YORK, April 1, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX ), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory ...

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases.

Plus, a first-quarter stock and bond market wrap up. We sell different types of products and services to both investment professionals and individual investors. These products and services are ...